What Nephrogenic Fibrosing Dermopathy Might Be

LeBoit, Philip E.

doi:10.1001/archderm.139.7.928

Cited by 86 publications

(57 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4,30 In a small cohort, others (W. A. H.) identified an inverse relationship between Gd levels in tissue and relative doses of ESA. These investigators speculated that this might be a result of a ''threshold phenomenon'' for NSF that, potentially, might be reached in a variety of ways (a greater amount of Gd accumulation, or a lesser amount of Gd accumulation with other profibrotic events, eg, high ESA dosing).…”

Section: Discussionmentioning

confidence: 99%

Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: A single-center experience

Lemy

Marmol

Kolivras

et al. 2010

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: A single-center experience

Lemy

Marmol

Kolivras

et al. 2010

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

show abstract

“…Based on clinical criteria, it was clear that the condition was distinct from morphea or scleroderma. Thus, from the beginning the working assumption of ''a possible scleromyxedema, related to transplantation'' was made (1). With an increasing number of patients without a history of transplantation but with a history of renal dialysis, it became clear that there were some differences between this ''new'' disorder and scleromyxedema.…”

mentioning

confidence: 99%

“…First, it was not possible to detect a paraprotein in the serum; this argued against scleromyxedema, as IgG k would be expected in such patients. Second, the clinical distribution of lesions favoring the extremities and sparing the face was the opposite of the expected localization in scleromyxedema (1,2). Therefore, the disease was described as ''Scleromyxoedema-like cutaneous diseases in renal dialysis patients'' (3).…”

mentioning

confidence: 99%

Nephrogenic systemic fibrosis: Clinical spectrum of disease

Mayr

Burkhalter

Bongartz

2009

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Nephrogenic systemic fibrosis (NSF) is a rare systemic fibrosing disorder that primarily affects the skin and the subcutaneous structures. Also, there are reports of involvement of deeper structures and organs in the human body, but the confirmation of systemic involvement is complicated by overlap of other disease processes that occur in patients with severe renal impairment. The disorder leads to significant disability and is an important contributing factor of death. Virtually all patients who developed NSF suffered from endstage renal disease (ESRD) or severe chronic kidney disease (CKD) or from an acute acquired kidney injury (AKI). There is an increase in evidence that a causal relation between gadolinium‐based contrast agents (Gd‐CA) and NSF is probable. Therefore, advanced kidney injury and the exposure to Gd‐CA are regarded as prerequisites to develop NSF. Overall, the prognosis is poor and there is no established therapy that shows a consistent benefit. The purpose of this review is to discuss the clinical spectrum of the disease. The clinical presentation, role of co‐morbidity in disease development and manifestation, time course, prognosis, outcome, and epidemiological aspects are especially reviewed. J. Magn. Reson. Imaging 2009;30:1289–1297. © 2009 Wiley‐Liss, Inc.

show abstract

“…On 7 February 2007, the medical community was informed that gadodiamide (Omniscan) is now not only contraindicated in patients with end-stage renal disease (ESRD), but also in pre-or postoperative liver transplantation patients and, due to their renal-organ immaturity, in newborns and infants up to 1 year old. This change in policy was motivated by recent reports of a possible link between the use of gadodiamide and the development of so-called "nephrogenic systemic fibrosis" (NSF) [1][2][3][4] in patients with renal failure. This discovery came as quite a surprise to the nephrology and radiology communities.…”

mentioning

confidence: 99%

“…A glimpse into medical literature reveals approximately 200 cases of NSF, previously known as nephrogenic fibrosing dermopathy (NFD) [1][2][3][4][5][6]. One pediatric case is published in this issue [7].…”

mentioning

confidence: 99%